Of interest here, in the context of cancer biology and p53-deficient tumours, CTR mediates the action of one of its ligands (amylin) on glycolysis and promotes apoptosis in thymic lymphoma cells.32,33 The outcomes of this study and our model suggest that agonists of CTR might also prove to represent a novel class of antitumour drugs that promote apoptosis in the context of the cancer microenvironment for particular classes of cancer cell genotypes. The gene discussed is IAPP; the disease is cancer.